|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
540.21 Million
|
|
Market
Size (2030)
|
USD
1209.14 Million
|
|
CAGR
(2025-2030)
|
14.37%
|
|
Fastest
Growing Segment
|
Kits
and Reagents
|
|
Largest
Market
|
China
|
Market Overview
Asia-Pacific
Protein Expression Market was valued at USD 540.21 million in 2024 and is
expected to reach USD 1209.14 million by 2030 with a CAGR of 14.37% during the
forecast period. The market's growth is driven by significant advances in
biotechnology and rising demand for recombinant proteins in a variety of
applications, including research, therapeutics, and industry.
Key Market Drivers
Rising Demand for Biopharmaceuticals
The
growing demand for biopharmaceuticals in the Asia-Pacific region is a
significant driver for the protein expression market. As biotechnology
advances, the development of therapeutic proteins, such as monoclonal
antibodies, vaccines, and recombinant proteins, has become a focal point for
the healthcare sector. These biopharmaceuticals are used to treat a wide range
of conditions, from cancer to autoimmune diseases, and the increasing need for
these treatments is driving the demand for protein expression technologies. The
Asia-Pacific region, with its rapidly growing pharmaceutical industry and
increasing investment in biotechnology, presents a huge market opportunity for
protein expression solutions. As biopharma companies in the region expand their
research and manufacturing capabilities, the adoption of advanced protein
expression systems, including mammalian cell systems and E. coli expression
systems, is rising, contributing to market growth.
In
the last 12 months alone, close to 20 protein therapeutics have been approved
by the USFDA, for the treatment of myriads of chronic diseases, including
cancers, immune disorders, infections, and diabetes. Moreover, since 2023, more
than 6,500 patents related to protein expression have been granted.
Advances in Biotechnology and
R&D Investment
Continued
advancements in biotechnology, along with increased investments in research and
development (R&D), are accelerating the growth of the protein expression
market in the Asia-Pacific region. For instance, on the private investment side, more than $1 billion (USD) has now been invested in APAC’s alternative protein sector. Private investments climbed by 45 percent year-over-year to reach $556 million (USD) investment in 2022. Countries such as China, India, and Japan
are significantly increasing their R&D expenditure in life sciences, aiming
to bolster their biotechnological capabilities. The integration of
state-of-the-art technologies, including CRISPR gene editing, synthetic
biology, and high-throughput screening, is revolutionizing protein expression,
enabling the production of complex proteins with higher yields and better
quality. These technological advancements are also facilitating the development
of novel biologics and biosimilars, expanding the range of therapeutic proteins
available on the market. This trend is especially evident in the increasing
number of biotech startups and partnerships, which are further driving protein
expression technologies and services in the region.
Public funding for alternative proteins in APAC increased by 207 percent year-over-year between 2021 and 2022, from $31 million to $94 million (USD). Private funding also increased by 45 percent from $383 million to $556 million in the same period.
Download Free Sample Report
Key Market Challenges
High Production Costs and
Scalability Issues
One
of the key challenges faced by the Asia-Pacific protein expression market is
the high cost of protein production and scalability issues. Despite
advancements in expression systems, producing proteins on a large scale remains
a complex and expensive process. For instance, the need for specialized
equipment, high-quality culture media, and skilled professionals in the
production process can increase the overall cost. Additionally, achieving a
balance between product yield and quality is a constant challenge, particularly
for complex proteins. Small and medium-sized biotech companies, especially in
developing markets within the region, may find it difficult to meet these
production costs, hindering the widespread adoption of protein expression
technologies. To address this challenge, continued innovation in cost-effective
production platforms and more efficient scaling techniques will be crucial.
Regulatory Hurdles and
Compliance Issues
Another
significant challenge in the Asia-Pacific protein expression market is the
complex and sometimes inconsistent regulatory environment. Different countries
within the region have their own regulatory frameworks and guidelines for
protein production, which can be difficult for manufacturers to navigate. In
some instances, the approval process for biopharmaceuticals or protein-based
therapeutics can be lengthy and cumbersome, slowing down the commercialization
of new products. Stringent regulations around the use of genetically modified
organisms (GMOs), as well as evolving safety standards, can create compliance
challenges for companies. To ensure smooth market access, companies must ensure
their products meet the necessary regulatory requirements, which can involve
substantial time and financial investment.
Key Market Trends
Adoption of Cell-Free Protein
Expression Systems
One
of the emerging trends in the Asia-Pacific protein expression market is the
increasing adoption of cell-free protein expression systems. Unlike traditional
cell-based systems that require living cells to produce proteins, cell-free
systems use extracts from cells or simplified cell-free systems that allow for
the rapid production of proteins without the need for cell culture. This
innovation significantly reduces production time and costs, offering greater
flexibility and scalability. Cell-free systems are particularly beneficial for
producing difficult-to-express proteins, which are often challenging to produce
using conventional expression methods. As biotech companies look for faster and
more cost-efficient production methods, the demand for cell-free protein
expression platforms is growing in the region, driving market expansion.
Focus on Biosimilars and
Biobetters
A
key trend shaping the Asia-Pacific protein expression market is the increasing
focus on biosimilars and biobetters. As patent expirations for blockbuster
biologic drugs occur, the demand for biosimilars—biologic products that are like,
but not identical to, an original product—has surged. This trend is
particularly prominent in countries like India and China, which have strong
manufacturing capabilities and cost-effective production environments. Protein
expression technologies play a crucial role in the development of biosimilars,
as they are used to produce therapeutic proteins that mirror the originals.
Furthermore, the market is also witnessing a rise in "biobetters,"
which are modified versions of existing biologics with improved
characteristics, such as enhanced efficacy or fewer side effects. These trends
are expected to drive innovation in protein expression systems and foster
growth in the market as more biopharma companies turn to protein expression
technologies to develop new biologics and biosimilars.
Segmental Insights
Application Insights
Based
on the application, the biopharmaceutical manufacturing category was dominating
the market due to the increasing demand for biopharmaceuticals in the region.
As biotechnology continues to evolve, the development of biologic drugs such as
monoclonal antibodies, vaccines, and recombinant proteins has become a critical
part of the healthcare sector. Protein expression technologies are essential in
producing these biologics, which are used in the treatment of a variety of
complex diseases, including cancer, autoimmune disorders, and genetic diseases.
The growth of the biopharmaceutical industry in countries like China, India,
and Japan, coupled with advancements in biotechnology, has driven the need for
efficient and scalable protein expression systems. These systems enable the
high-yield production of therapeutic proteins, which are crucial for meeting
the growing demand for biopharmaceutical products in the region.
Download Free Sample Report
Country Insights
Based
on the region, China was dominating the Asia-Pacific protein expression market
due to its large population, rapid advancements in biotechnology, and strong
presence in the biopharmaceutical manufacturing sector. As the world's most
populous country, China has a substantial demand for protein-based
therapeutics, particularly in the treatment of chronic diseases such as
diabetes, cancer, and autoimmune disorders. The Chinese government has heavily
invested in expanding the biotechnology sector, improving healthcare infrastructure,
and supporting the development of biopharmaceuticals. This has created a
favorable environment for the growth of protein expression technologies, which
are essential for producing therapeutic proteins used in biologics and
biosimilars.
Recent Developments
- In
May 2024, ExpressionEdits raised $13 million in seed funding. The round was
co-led by Octopus Ventures and redalpine, with contributions from BlueYard
Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.
- In
November 2023, Lonza launched a new cell line GS Effex® that produces Fc
domains free of fucose. It leads to an increase of the antibody-dependent
cellular cytotoxicity (ADCC) function and therapeutic potency of the final
antibody.
- In
July 2023, the company launched a new TheraPRO CHO Media System in order to
optimize the production of therapeutic proteins from GS-CHO cell lines.
Key Market Players
- GenCefe Co., Ltd.
- Takara Bio Inc.
- Merck KGaA
- Charles River Laboratories
- Agilent Technologies Inc.
- GeNext Genomics
- Thermo Fisher Scientific Inc.
- WuXi Biologics
- Ajinomoto Bio-Pharma Services
- Domainex
|
By Application
|
By Product
|
By End User
|
By Country
|
- Biopharmaceutical
Manufacturing
- Research
and Development
- Industrial
Usage
|
- Kits
and Reagents
- Expression
Vectors
- Competent
Cells
- Plastic
Consumables and Accessories
|
- Biopharmaceutical
and Biotech Companies
- CRO
and CDMO
- Academic
& Research Institutes
- Others
|
- China
- Japan
- South
Korea
- India
- Malaysia
- Indonesia
- Vietnam
- Australia
- Thailand
- Philippines
|
Report Scope:
In this report, the Asia-Pacific Protein Expression
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Asia-Pacific Protein Expression Market, By Application:
o Biopharmaceutical Manufacturing
o Research and Development
o Industrial Usage
- Asia-Pacific Protein Expression Market, By Product:
o Kits and Reagents
o Expression Vectors
o Competent Cells
o Plastic Consumables and Accessories
- Asia-Pacific Protein Expression Market, By End User:
o Biopharmaceutical and Biotech Companies
o CRO and CDMO
o Academic & Research Institutes
o Others
- Asia-Pacific Protein Expression Market, By Country:
o China
o Japan
o South Korea
o India
o Malaysia
o Indonesia
o Vietnam
o Australia
o Thailand
o Philippines
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Asia-Pacific
Protein Expression Market.
Available Customizations:
Asia-Pacific Protein Expression Market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Asia-Pacific Protein Expression Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at sales@techsciresearch.com